2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer
Petrylak D, Quinn D, Dreicer R, Antonarakis E, Shore N, Corman J, Concepcion R, Pieczonka C, Chang N, DeVries T, Sheikh N, Drake C. 2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer. European Journal Of Cancer 2015, 51: s483. DOI: 10.1016/s0959-8049(16)31345-4.Peer-Reviewed Original Research